510 related articles for article (PubMed ID: 31109439)
1. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them].
Shi Y; Li P; Li B; Zhang F; Huang S; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):299-305. PubMed ID: 31109439
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
4. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L
Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
[TBL] [Abstract][Full Text] [Related]
7. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
8. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
[TBL] [Abstract][Full Text] [Related]
9. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
11. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
12. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY; Ke EE; Yang JJ; Sun YL; Yan HH; Zheng MY; Bai XY; Wang Z; Su J; Chen ZH; Zhang XC; Dong ZY; Wu SP; Jiang BY; Chen HJ; Wang BC; Xu CR; Zhou Q; Mei P; Luo DL; Zhong WZ; Yang XN; Wu YL
Lung Cancer; 2017 Dec; 114():96-102. PubMed ID: 29173773
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer].
Wang M; Ren D; Guo C; Ding X; Wang H
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):594-599. PubMed ID: 30172266
[TBL] [Abstract][Full Text] [Related]
18. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
19. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X.
Hao Y; Xu M; Zhou H; Si J; Fang Y; Xu C; Song Z
Med Oncol; 2022 Dec; 40(1):34. PubMed ID: 36460861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]